脂质体紫杉醇联合奈达铂双周方案治疗晚期非小细胞肺癌21例临床观察

Efficacy of biweekly-regimens of paclitaxel liposome combined with nedaplatin on advanced non-small cell lung cancer

目的观察脂质体紫杉醇联合奈达铂双周方案治疗晚期体力状态较差的非小细胞肺癌(NSCLC)的近期疗效和毒副作用。方法 21例晚期NSCLC患者(ECOG PS=2或3),采用脂质体紫杉醇100 mg/m2静滴d1,d14,联合奈达铂50 mg/m2静滴d1,d14,每4周为1疗程,两个疗程后评价疗效和毒性。结果 21例患者均可评价近期疗效:初治的11例患者中,完全缓解0例,部分缓解3例,稳定6例,进展2例,有效率(CR+PR)为27%,疾病控制率(CR+PR+SD)为82%。复治的10例患者中,完全缓解0例,部分缓解1例,稳定4例,进展5例,有效率为10%,疾病控制率为50%。毒副作用主要为骨髓抑制,以白细胞和血小板减少为主;非血液学毒副作用以肌痛及关节酸痛、脱发为主。结论脂质体紫杉醇联合奈达铂双周方案治疗体力状态较差的晚期非小细胞肺癌疗效较好,毒副作用可以耐受。

Objective To investigate the short-term efficacy and toxicity of biweekly-regimens of paclitaxel liposome combined with nedaplatin in the treatment of advanced non-smaU cell lung cancer （NSCLC） with poor perfor- mance status. Methods 21cases with advanced NSCLC （ECOG PS=2 or 3） treated with paclitaxel liposome 100mg/m2 ivgtt on day 1, 14 plus nedaplatin 50mg/m2 ivgtt on day 1,14. Every 4 weeks was one cycle. The efficacy and toxicity were evaluated after 2 cycles. Results All the 21 patients can be evaluated efficacy. Of 11 untreated cases, there were none ofCR, 3 cases of PR,6 cases of SD and 2 cases of PD. The response rate （CR＋PR） reached 27%, and the dis- ease control rate （ DCR, CR＋PR＋SD） reached 82%. Of 10 retreated cases, there were none of CR, I cases of PR, 4 cases of SD and 5 cases of PD. The response rate reached 10%, and the disease control rate reached 50%. Major ad- verse effects were myelosuppression, including neutropenia and thrombocytopenia. The non-haematological toxicity was myalgia, arthralgia and hair loss. Conclusion Biweekly-regimens of paclitaxe! liposome and nedaplatin is an ef- fective treatment regimen for advanced NSCLC patients with poor performance status, with tolerable adverse effect.